Altered cell subpopulations natural killer cell phenotypes patients progressive systemic sclerosis Scleroderma progressive systemic sclerosis PSS abnormal cell immunoregulation present study lymphocyte phenotypes patients PSS normal control subjects flow cytometry monoclonal antibodies total suppressor helper helper-inducer suppressor-inducer human leukocyte antigen DR+B DR+T natural killer subsets cells Patients PSS normal subjects percentages similar several patients rheumatoid arthritis T+DR+ cells Patients PSS late-limited generalized disease percentages percentages cells patients early stage disease results significant unique alterations patients PSS useful stage disease activity therapy define immunologic defects 